Thursdays, January 21, 2021; 8:45 AM - 10:15 AM
Section outline
-
Lecture 3: Measuring Outcomes and Adverse Effects
Clinical outcomes and alternatives. Defining adverse events; elicited vs. volunteered; nuisance adverse events; pitfalls of attribution of cause; FDA adverse events classifications.
Faculty: Dennis Black
Location (Access restricted to registered students): Zoom URL
-
Lecture 3 File
-
Lecture 3A Media Resource
-
Lecture 3B Media Resource
-
Workshop Slides_01.21.2021 File
-
Workshop 3 Video_01.21.2021 Media Resource
-
Psaty BM, Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. JAMA. 2008 Mar 26;299(12):1474-6. File
-
Bent S, et al. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med. 2006 Feb 21;144(4):257-61. File
-
Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021 Jan 9;397(10269):72-74. doi: 10.1016/S0140-6736(20)32623-4. Epub 2020 Dec 8. PMID: 33306990. File
Please read this article prior to Thursday's workshop
-
Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. File
Please read this article prior to Thursday's workshop
-
Homework Assignment for Lecture 3 File
-
Homework Assignment for Lecture 3 - Answer Key File